Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRICOM-CEA(6D)
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
A therapeutic cancer vaccine platform consisting of a recombinant viral vector (either vaccinia or fowlpox) engineered to express the tumor-associated antigen carcinoembryonic antigen (CEA) with an enhancer agonist epitope (designated 6D), along with a TRIad of COstimulatory Molecules (B7.1, ICAM‑1, and LFA‑3; collectively called TRICOM). The addition of these costimulatory molecules is designed to enhance antigen-specific T-cell responses and antitumor activity by improving immune recognition and activation against CEA-expressing tumors. The platform has been evaluated in phase I clinical trials for patients with advanced cancers expressing CEA, including colorectal cancer and other carcinomas. It is developed primarily by the National Cancer Institute[1][2][4][7].
- Other names
- CEA/TRICOM vaccineCEA(6D)/TRICOM
02
Targets
CD58 (Leukocyte function-associated antigen 3)CD80 (T-lymphocyte activation antigen CD80)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ICAM1 (Intercellular Adhesion Molecule 1)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on TRICOM-CEA(6D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRICOM-CEA(6D).